Description
EptifibatideisaninhibitorofglycoproteinGPIIb/IIIathatexhibitsantiplatelet/antithromboticactivity.Eptifibatideinhibitsfibrinogen-mediatedplateletaggregationandisclinicallyusedtotreatacutecoronarysyndrome.
EptifibatideisaninhibitorofglycoproteinGPIIb/IIIathatexhibitsantiplatelet/antithromboticactivity.Eptifibatideinhibitsfibrinogen-mediatedplateletaggregationandisclinicallyusedtotreatacutecoronarysyndrome.
CasNo. | 188627-80-7 |
---|---|
Purity | ≥98% |
Formula | C35H49N11O9S2 |
FormulaWt. | 832.4 |
ChemicalName | N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-L-Cysteinamide,cyclic(1-6)-disulfide |
IUPACName | 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazABIcyclo[21.3.0]hexacosan-6-yl]aceticacid |
Synonym | Integrilin |
Appearance | Whitetooffwhitepowder |
StoreTemp | -20°C |
---|---|
ShipTemp | Ambient |
InfoSheet | E6376InfoSheetPDF |
---|
AngiolilloDJ.Theevolutionofantiplatelettherapyinthetreatmentofacutecoronarysyndromes:fromaspirintothepresentday.Drugs.2012Nov12;72(16):2087-116.PMID:23083110.
GurbelPA,GalbutB,BlidenKP,etal.Effectofeptifibatideforacutecoronarysyndromes:rapidversuslateadmiNISTration--therapeuticyieldonplatelets(TheEARLYPlateletSubstudy).JThrombThrombolysis.2002Dec;14(3):213-9.PMID:12913401.